|

Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation

RECRUITINGPhase 2Sponsored by Technische Universität Dresden
Actively Recruiting
PhasePhase 2
SponsorTechnische Universität Dresden
Started2025-06-17
Est. completion2029-10-01
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06717958

Summary

maintenance of AML or MDS patients with known IDH1 mutation after allogeneic stem cell transplantation within past 100 days

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion criterion:

* AML or MDS with IDH1 mutation

Exclusion criteria:

* active GvHD (graft vs host disease) grade III-IV according to Harris criteria requiring steroids \>1mg/ kg prednisolone equivalent

Conditions3

AmlCancerMDS

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.